Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Marlo Blazer, PharmD, BCOP, Brian Seal, RPh, MBA, PhD, Huai-Che Shih, PhD, Augustina Ogbonnaya, MPH, Michael Eaddy, PharmD, PhD, Bruce J Dezube, MD

Blood (2016) 128 (22): 5540.

https://doi.org/10.1182/blood.V128.22.5540.5540

Published: 2016

Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 98.

https://doi.org/10.1182/blood.V128.22.98.98

Published: 2016

Journal Articles

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Ronan T Swords, MD PhD FRCPI, FRCPath, Michael R Savona, MD, Michael B Maris, MD, Harry P Erba, MD PhD, Jesus G. Berdeja, MD, James M. Foran, MD, Zhaowei Hua, PhD, Hélène M Faessel, PharmD, PhD, Ajeeta B Dash, PhD, Farhad Sedarati, PhD, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2014) 124 (21): 2313.

https://doi.org/10.1182/blood.V124.21.2313.2313

Published: 2014

Journal Articles

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

Daniel J. DeAngelo, MD, Ph.D, Harry P Erba, MD, Michael B Maris, MD, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Faiz Anwer, MD, Jessica K Altman, MD, Zhaowei Hua, Ph.D, Stephen J Blakemore, Ph.D, Hélène Faessel, Ph.D, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2013) 122 (21): 1443.

https://doi.org/10.1182/blood.V122.21.1443.1443

Published: 2013

Journal Articles

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

Ronan T Swords, MD, MRCPI, FRCPath, Harry P Erba, MD, PhD, Daniel J DeAngelo, MD, PhD, Peter G Smith, PhD, Michael D Pickard, MA, Bruce J. Dezube, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Bruno C. Medeiros, MD

Blood (2010) 116 (21): 658.

https://doi.org/10.1182/blood.V116.21.658.658

Published: 2010

Journal Articles

Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma.

Jatin J Shah, MD, R. Donald Harvey, PharmD, Owen A O'Connor, MD, PhD, Andrzej J Jakubowiak, MD, PhD, Mitchell R Smith, MD, PhD, Robert Z. Orlowski, MD, PhD, George J Mulligan, PhD, Peter G Smith, PhD, Michael D Pickard, MA, Bruce J. Dezube, MD, Sagar Lonial, MD

Blood (2010) 116 (21): 2801.

https://doi.org/10.1182/blood.V116.21.2801.2801

Published: 2010

NARROW

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only